vs
Side-by-side financial comparison of Ocugen, Inc. (OCGN) and PROTHENA CORP PUBLIC LTD CO (PRTA). Click either name above to swap in a different company.
On growth, PROTHENA CORP PUBLIC LTD CO posted the faster year-over-year revenue change (-99.0% vs -125.3%). Over the past eight quarters, PROTHENA CORP PUBLIC LTD CO's revenue compounded faster (NaN% CAGR vs NaN%).
Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases, including rare inherited retinal disorders and age-related eye conditions. It operates primarily in the North American market, with a pipeline covering gene therapies, biologics, and vaccine candidates targeting unmet medical needs.
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
OCGN vs PRTA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $-193.0K | $21.0K |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | 8805.7% | — |
| Net Margin | — | — |
| Revenue YoY | -125.3% | -99.0% |
| Net Profit YoY | — | 62.7% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $-193.0K | $21.0K | ||
| Q3 25 | $1.8M | $2.4M | ||
| Q2 25 | $1.4M | $4.4M | ||
| Q1 25 | $1.5M | $2.8M | ||
| Q4 24 | $764.0K | $2.1M | ||
| Q3 24 | $1.1M | $970.0K | ||
| Q2 24 | $1.1M | $132.0M | ||
| Q1 24 | $1.0M | $50.0K |
| Q4 25 | — | — | ||
| Q3 25 | $-20.1M | $-36.5M | ||
| Q2 25 | $-14.7M | $-125.8M | ||
| Q1 25 | $-15.3M | $-60.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-13.0M | $-59.0M | ||
| Q2 24 | $-15.3M | $66.9M | ||
| Q1 24 | $-11.9M | $-72.2M |
| Q4 25 | 8805.7% | — | ||
| Q3 25 | -1006.0% | -1666.3% | ||
| Q2 25 | -1004.7% | -1914.4% | ||
| Q1 25 | -979.1% | -2319.0% | ||
| Q4 24 | -1811.5% | — | ||
| Q3 24 | -1166.5% | -6857.0% | ||
| Q2 24 | -1354.0% | 44.2% | ||
| Q1 24 | -1204.7% | -163056.0% |
| Q4 25 | — | — | ||
| Q3 25 | -1144.5% | -1513.1% | ||
| Q2 25 | -1073.5% | -2845.4% | ||
| Q1 25 | -1036.5% | -2128.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1141.7% | -6082.6% | ||
| Q2 24 | -1339.2% | 50.7% | ||
| Q1 24 | -1175.9% | -144478.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.68 | ||
| Q2 25 | — | $-2.34 | ||
| Q1 25 | — | $-1.12 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-1.10 | ||
| Q2 24 | $-0.04 | $1.22 | ||
| Q1 24 | $-0.05 | $-1.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $307.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-12.2M | $280.5M |
| Total Assets | $43.5M | $326.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $307.5M | ||
| Q3 25 | — | $330.8M | ||
| Q2 25 | — | $371.4M | ||
| Q1 25 | $37.8M | $417.9M | ||
| Q4 24 | — | $471.4M | ||
| Q3 24 | — | $519.3M | ||
| Q2 24 | $15.7M | $564.1M | ||
| Q1 24 | $26.4M | $546.5M |
| Q4 25 | $-12.2M | $280.5M | ||
| Q3 25 | $3.5M | $295.0M | ||
| Q2 25 | $3.1M | $324.3M | ||
| Q1 25 | $15.9M | $437.7M | ||
| Q4 24 | $29.6M | $486.9M | ||
| Q3 24 | $40.6M | $534.4M | ||
| Q2 24 | $16.9M | $581.9M | ||
| Q1 24 | $30.3M | $502.4M |
| Q4 25 | $43.5M | $326.8M | ||
| Q3 25 | $57.6M | $352.6M | ||
| Q2 25 | $53.6M | $399.1M | ||
| Q1 25 | $64.5M | $495.3M | ||
| Q4 24 | $82.4M | $547.1M | ||
| Q3 24 | $61.9M | $595.3M | ||
| Q2 24 | $40.5M | $645.6M | ||
| Q1 24 | $51.8M | $623.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.0M | $-163.6M |
| Free Cash FlowOCF − Capex | $-14.0M | — |
| FCF MarginFCF / Revenue | 7251.8% | — |
| Capex IntensityCapex / Revenue | -18.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-57.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.0M | $-163.6M | ||
| Q3 25 | $-12.9M | $-40.6M | ||
| Q2 25 | $-10.7M | $-46.3M | ||
| Q1 25 | $-19.4M | $-53.4M | ||
| Q4 24 | $-10.4M | $-150.1M | ||
| Q3 24 | $-11.3M | $-45.2M | ||
| Q2 24 | $-9.9M | $16.0M | ||
| Q1 24 | $-10.6M | $-73.1M |
| Q4 25 | $-14.0M | — | ||
| Q3 25 | $-13.0M | — | ||
| Q2 25 | $-10.8M | — | ||
| Q1 25 | $-19.4M | — | ||
| Q4 24 | $-10.4M | — | ||
| Q3 24 | $-11.8M | — | ||
| Q2 24 | $-10.4M | — | ||
| Q1 24 | $-12.9M | — |
| Q4 25 | 7251.8% | — | ||
| Q3 25 | -742.4% | — | ||
| Q2 25 | -784.6% | — | ||
| Q1 25 | -1308.1% | — | ||
| Q4 24 | -1358.2% | — | ||
| Q3 24 | -1036.9% | — | ||
| Q2 24 | -913.6% | — | ||
| Q1 24 | -1276.8% | — |
| Q4 25 | -18.1% | — | ||
| Q3 25 | 5.2% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 44.6% | — | ||
| Q2 24 | 45.0% | — | ||
| Q1 24 | 232.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
